Tallahassee Journal

Pancreatic Ductal Adenocarcinoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Key Companies

 Breaking News
  • No posts were found

Pancreatic Ductal Adenocarcinoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Key Companies

January 25
08:34 2023
Pancreatic Ductal Adenocarcinoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Market. 

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis

Pancreatic Ductal Adenocarcinoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Pancreatic Ductal Adenocarcinoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Route of Administration

The Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:

  • Oral

  • Intravenous

  • Subcutaneous


Molecule Type

Products have been categorized under various Molecule types, such as:

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy


Pancreatic Ductal Adenocarcinoma Emerging Therapies Mechanism of Action (MOA) Types:

  • Interleukin 8A; 8 receptor antagonist

  • Capillary permeability stimulant

  • Antibody-dependent cell cytotoxicity

  • Ras protein inhibitor stimulant

  • Focal adhesion protein-tyrosine kinase inhibitor

  • Autophagy-related protein-1 homolog inhibitor

  • Polo-like kinase 1 inhibitor


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Learn How the Ongoing Clinical & Commercial Activities will Affect the Pancreatic Ductal Adenocarcinoma Therapeutic Segment @


Pancreatic Ductal Adenocarcinoma Therapeutics Landscape

Surgical resection and chemotherapy (gemcitabine and FOLFIRINOX, a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) has improved the survival of patients with early-stage pancreatic cancer, but these treatments are not sufficient for patients with late stages of the disease). Immunotherapy began a new era in the field of cancer treatment; it is challenging in the context of PDAC as this type of cancer has a nonimmunogenic, immune-suppressive, and therapy-resistant microenvironment. Many molecules currently being tested in clinical trials against PDAC are CCR2, a chemokine receptor that mediates the chemotaxis of immune cells.

There are approx. 80+ key companies developing therapies for Pancreatic Ductal Adenocarcinoma. Currently, XOMA is leading the therapeutics market with its Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market Include:

  • Cardiff Oncology

  • XOMA

  • Alphamab

  • Cantargia

  • RenovoRx

  • Syntrix Biosystems

  • Eucure Biopharma

  • Panbela Therapeutics

  • Jeil Pharmaceutical

  • Elicio Therapeutics

  • Cend Therapeutics

  • SignalChem Lifesciences

  • Bristol-Myers Squibb

  • AstraZeneca

  • REVOLUTION Medicines

  • Arcus Biosciences

  • ZielBio

  • Surface Oncology

  • Incyte Corporation

  • I-Mab Biopharma

  • Medicenna Therapeutics

  • Tarveda Therapeutics

And Many Others

Pancreatic Ductal Adenocarcinoma Therapies Covered in the Report Include:

  • Onvansertib: Cardiff Oncology

  • Nadunolimab: Cantargia

  • Zimberelimab: Arcus Biosciences

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns

4. Pancreatic Ductal Adenocarcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase-III)

7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)

8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pancreatic Ductal Adenocarcinoma Discontinued Products

13. Pancreatic Ductal Adenocarcinoma Product Profiles

14. Key Companies in the Pancreatic Ductal Adenocarcinoma Market

15. Key Products in the Pancreatic Ductal Adenocarcinoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Pancreatic Ductal Adenocarcinoma Unmet Needs

18. Pancreatic Ductal Adenocarcinoma Future Perspectives

19. Pancreatic Ductal Adenocarcinoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



Other Trending Healthcare Reports By DelveInsight

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market

DelveInsight’s “Cough in Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cough in Idiopathic Pulmonary Fibrosis (IPF) market size, shares, and trends analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/